-The Hindu Bayer's plea dismissed by the Intellectual Property Appellate Board The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs. Disposing an appeal filed by Bayer...
More »SEARCH RESULT
Total Matching Records found : 124
Bayer plea dismissed, Natco allowed to sell patent cancer drug
-The Business Standard Chennai: The Intellectual Property Appellate Board (IPAB) today upheld a compulsory licence issued by the Controller of Patents to Hyderabad-based Natco Pharma Ltd, a generic drug maker, to manufacture and sell a cancer drug of Bayer Corp in India. IPAB, however, made changes in the licence order by increasing the royalty payment to Bayer Corp for Nexavar, used to treat liver and kidney cancer, from six per cent to...
More »Business by other means -Ajoy Ashirwad Mahaprashasta
-Frontine Walmart’s disclosure that it spent huge amounts of money on lobbying in India and the allegation that it entered the retail sector through indirect means highlight the power of global capital in dictating the country’s policies. The world’s largest multi-brand retailer Walmart’s disclosure to the United States Senate that it had spent $25 million (Rs.135 crore) since 2008 on its various lobbying activities, which include enhancing access to the Indian...
More »Growing crisis of drug prices
-The Hindu India’s Drug Price Control Order, which is vital to the availability of affordable essential medicines, has been whittled down to the point of becoming insignificant. While the number of price-controlled medicines has dwindled over the past three decades, from 347 to 74, the pharmaceutical industry has been pursuing super profits. The High Level Expert Group of the Planning Commission on Universal Health Coverage noted in its report that price...
More »SC to Examine New Drug Pricing Policy
-Outlook The Supreme Court today said it would examine the National Pharmaceutical Pricing Policy after it is notified with the Centre promising to do it within two weeks. A bench headed by Justice G S Singhvi granted two weeks time to the Centre to issue notification and posted the matter for hearing on December 12. Additional Solicitor General Siddharth Luthra informed the court that the Cabinet had approved the policy that will bring...
More »
